Tesamorelin is FDA-approved only to reduce excess abdominal fat in adults living with HIV and lipodystrophy (EGRIFTA SV label revised February 2024). The dated October 2024 FDA briefing reported no FDA-approved drug product containing ipamorelin; its cited human evidence is limited to short-term hormone pharmacology and a surgical condition—not healthy-adult body composition.
Start with the regulatory question
Tesamorelin is a growth-hormone-releasing-factor (GHRF) analogue—a lab-made molecule modeled on a natural signal that tells the body to release growth hormone. The FDA-approved EGRIFTA SV label gives it a specific indication: reducing excess abdominal fat in adults living with HIV and lipodystrophy, a condition involving changes in how the body stores fat. The same label says long-term cardiovascular safety has not been established and that it is not indicated for weight-loss management. That is a narrow indication for a defined clinical population, not a general approval for changing body composition in otherwise healthy adults.[1]
Ipamorelin is a growth-hormone secretagogue, meaning a substance that prompts the body to release growth hormone. It does this through the ghrelin receptor, a cell receptor that responds to the hormone ghrelin. An FDA briefing dated October 2024 states that ipamorelin free base and ipamorelin acetate were not components of an FDA-approved drug. The briefing reviewed whether either substance should be included on a list of bulk substances that may be used in certain pharmacy-compounded products; it said the available information weighed against placement. That dated review is not presented here as a current final rule. A compounded product is not the same thing as an FDA-approved product, and online availability does not establish an approved use.[2]
What tesamorelin studies show
The central tesamorelin evidence comes from randomized, placebo-controlled studies—trials in which people are assigned by chance to the study treatment or an inactive comparison—in adults living with HIV who had excess abdominal fat, generally while receiving antiretroviral therapy, medicines used to treat HIV. The main outcome was visceral adipose tissue (VAT), the fat stored inside the abdomen, rather than a broad promise of weight loss. In one trial with a longer safety extension, the initial study period assessed VAT and other body-composition and safety measures; the extension examined what happened when participants continued or stopped assigned treatment.[3]
A pooled analysis of two phase 3, later-stage trials included 806 adults with HIV and excess abdominal fat who were receiving antiretroviral treatment. It reported reduced VAT and changes in some body-image and lipid, or blood-fat, measures, while also describing the limits of the follow-up. A separate randomized clinical trial in 50 adults with HIV and abdominal fat accumulation found reductions in visceral and liver fat over six months. These are clinically relevant findings for the studied population, but VAT reduction is not synonymous with weight-loss treatment, and results from HIV-associated lipodystrophy should not be transferred to a different population without direct evidence.[4][5]
The label also matters because it sets boundaries around the trial evidence. It describes weight-neutral effects rather than a weight-loss indication, does not establish long-term cardiovascular safety, and warns about increased risk of neoplasms, meaning new abnormal tissue growths that can include cancer, elevated insulin-like growth factor 1 (IGF-1), a growth-related signal in the body, fluid retention, glucose intolerance or diabetes, hypersensitivity, and injection-site reactions. Those warnings do not mean that every person will experience each event; they mean the approved product's risk information cannot be replaced by a marketing summary or by an appealing mechanism.[1]
What ipamorelin studies actually measured
The human ipamorelin literature answers different questions. A pharmacokinetic and pharmacodynamic study—measuring how the body handles ipamorelin and how the body responds to it—in healthy male volunteers measured a short episode of growth-hormone release. It did not test fat loss, muscle gain, healthy aging, or long-term clinical outcomes. A change in a hormone concentration is a biological observation; by itself, it does not show that a person will feel better or become healthier.[7]
A separate phase 2, or mid-stage, proof-of-concept trial—an early test of whether an approach might work—studied 117 adults in the hospital after small- or large-bowel resection, not people seeking body-composition changes. The study compared ipamorelin with placebo for postoperative ileus, the temporary slowing of bowel movement after surgery. Although the treatment was described as tolerated in that short study, the publication reported no significant difference between groups in its key or secondary efficacy analyses. A surgical inpatient result cannot be used as evidence for a wellness, performance, or general-adult indication.[6]
FDA's dated compounding briefing also identified an evidence and product-quality problem: neither ipamorelin form had an applicable USP or National Formulary drug-substance monograph, a recognized quality description for a drug ingredient, or was a component of an FDA-approved drug. FDA noted gaps in characterization, including impurities, aggregates, and bacterial endotoxins, and said potential immunogenicity, meaning the ability to trigger an immune response, could not be ruled out. These are especially important caveats for an injectable peptide, where the specific formulation, manufacturing controls, route, and duration can change the safety question.[2]
Visit the store directly, or keep exploring the evidence library. No email signup is needed to visit the store.
Why this is not a head-to-head contest
There is no cited head-to-head clinical trial comparing tesamorelin with ipamorelin for the same condition, population, outcome, and follow-up. Tesamorelin has a regulatory indication and a body of randomized evidence in HIV-associated lipodystrophy. Ipamorelin has human pharmacology data and a short postoperative-ileus trial, but those studies do not establish a comparable body-composition benefit. Comparing a VAT endpoint with a transient growth-hormone response would be comparing different kinds of evidence, not ranking two products on one scale.[2][3][4][6][7]
The healthy-adult boundary is particularly important. The tesamorelin trials cited here enrolled adults with HIV-associated abdominal fat accumulation, while the healthy ipamorelin study measured pharmacology rather than a health outcome. Nothing in these sources supports extrapolating either evidence base to healthy adults for fat loss, strength, recovery, longevity, or other popular wellness claims. The absence of evidence for an outcome is not proof that the outcome is impossible; it is a reason not to present it as established.[1][3][4][7]
Safety and evidence limits
For tesamorelin, safety information is tied to an FDA-reviewed product and a defined indication, but the label still calls for careful attention to malignancy history, IGF-1, glucose, fluid retention, hypersensitivity, and the unknowns around long-term cardiovascular safety. The label's risk information is not a dosing guide here; it is a reminder that a narrow approval does not mean a universal safety profile.[1]
For ipamorelin, the principal limitation is not simply that the evidence is smaller. There is no FDA-approved ipamorelin drug product, no established indication for healthy-adult body composition, and no basis in the cited studies for treating a short-term hormone response as proof of long-term benefit. FDA's concerns about peptide characterization, impurities, aggregation, and possible immune reactions add uncertainty that cannot be resolved by calling a preparation “compounded” or “research grade.”[2][6][7]
A more useful way to read claims
When a source says that a peptide “increases growth hormone,” ask what was measured, in whom, for how long, and against what comparator. When it says that a peptide “reduces abdominal fat,” ask whether the outcome was visceral fat, subcutaneous fat, scale weight, or a patient-important outcome—and whether the participants match the person being discussed. These questions do not make the science less interesting; they prevent a mechanism, a surrogate, and an approved indication from being treated as interchangeable.[1][3][4][5][7]
The fairest bottom line is therefore descriptive rather than promotional: tesamorelin has evidence and FDA labeling for a narrow HIV-associated lipodystrophy use, with important safety and durability limits. Ipamorelin has early human pharmacology and a negative-for-efficacy postoperative study, alongside FDA-documented regulatory and product-quality uncertainty. Neither set of sources supports extrapolation to healthy adults, and neither comparison table nor questionnaire can substitute for an individualized clinical assessment.[1][2][3][4][6][7]
At a glance
| Topic | Tesamorelin | Ipamorelin |
|---|---|---|
| U.S. regulatory status[1][2] | EGRIFTA SV has an FDA label for reducing excess abdominal fat in HIV-infected adults with lipodystrophy; it is not indicated for weight-loss management. | The dated October 2024 FDA briefing says neither ipamorelin free base nor acetate is a component of an FDA-approved drug; its compounding review is not approval or a current final rule. |
| Populations in the cited clinical evidence[3][4][6][7] | Adults with HIV-associated excess abdominal fat or lipodystrophy, generally receiving antiretroviral therapy. | Healthy male volunteers for pharmacology, and hospitalized adults after bowel resection for a postoperative-ileus trial. |
| What was measured[3][4][6][7] | Visceral adipose tissue and related body-composition, metabolic, and safety outcomes. | Pharmacokinetics and a transient growth-hormone response; one separate study assessed postoperative gastrointestinal recovery. |
| Healthy-adult body-composition evidence[1][3][4][6][7] | Not established by the cited trials; the FDA indication is the narrower HIV-associated population. | Not established by the cited volunteer pharmacology study or postoperative-ileus trial. |
| Safety context[1][2] | FDA labeling includes warnings involving neoplasms, IGF-1, glucose, fluid retention, hypersensitivity, injection sites, and unknown long-term cardiovascular safety. | FDA identified limited characterization and possible impurity, aggregation, and immunogenicity concerns; there is no approved product label to define a comparable safety profile. |
| Can one evidence base substitute for the other?[1][2][3][4][6][7] | No. Its evidence is condition- and population-specific and is not a general wellness claim. | No. Its cited human studies do not supply an equivalent VAT or healthy-adult outcomes trial. |
Questions readers ask
Is tesamorelin a general weight-loss medication?
No. The EGRIFTA SV FDA label specifies reduction of excess abdominal fat in HIV-infected adults with lipodystrophy and explicitly says it is not indicated for weight-loss management. The label also describes a weight-neutral effect, so a general weight-loss framing is not supported by the cited source.[1]
Is ipamorelin FDA-approved?
The FDA briefing document used for this article states that ipamorelin free base and ipamorelin acetate were not components of an FDA-approved drug. A compounded preparation may be available under applicable compounding rules, but that availability is not the same as FDA approval or an FDA-approved indication.[2]
Does a growth-hormone response prove a health benefit?
No. The healthy-volunteer ipamorelin study measured pharmacokinetics and a short growth-hormone response. It did not establish fat loss, muscle gain, recovery, longevity, or long-term safety. Hormone biology and patient-important outcomes are different levels of evidence.[7]
Can tesamorelin's HIV trial results be applied to healthy adults?
Not on the basis of these sources. The randomized tesamorelin studies enrolled adults with HIV-associated abdominal fat accumulation or lipodystrophy. Their results address that clinical context; they do not establish effects in healthy adults with a different baseline risk, physiology, and reason for treatment.[1][3][4][5]
What did the ipamorelin postoperative study find?
It studied hospitalized adults after bowel resection. The publication reported that there were no significant differences between ipamorelin and placebo in its key and secondary efficacy analyses. That setting and endpoint do not answer questions about healthy-adult body composition.[6]
Why does formulation matter for ipamorelin?
FDA's compounding review identified gaps involving characterization, impurities, aggregates, and bacterial endotoxins, and said potential immunogenicity could not be ruled out. An ingredient name alone cannot establish that different compounded preparations have the same quality, exposure, or safety profile.[2]
Sources
References
- EGRIFTA SV (tesamorelin) prescribing informationU.S. Food and Drug Administration label, revised February 2024; indication, limitations of use, warnings, and adverse-reaction information.
- FDA briefing document: Evaluation of ipamorelin-related bulk drug substances for inclusion on the 503A Bulks ListPharmacy Compounding Advisory Committee materials, October 2024; regulatory status, clinical evidence review, characterization, impurity, aggregation, and immunogenicity caveats.
- Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation: a randomized placebo-controlled trial with a safety extensionFalutz et al., Journal of Acquired Immune Deficiency Syndromes, 2010;53(3):311–322; randomized trial and extension in adults with HIV-associated abdominal fat accumulation.
- Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension dataFalutz et al., The Journal of Clinical Endocrinology and Metabolism, 2010;95(9):4291–4304; pooled randomized phase 3 evidence with safety-extension data.
- Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trialStanley et al., JAMA, 2014;312(4):380–389; randomized placebo-controlled clinical trial of visceral and liver fat outcomes.
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patientsBeck et al., International Journal of Colorectal Disease, 2014;29(12):1527–1534; phase 2 inpatient trial with safety and postoperative gastrointestinal efficacy outcomes.
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone-releasing peptide, in human volunteersGobburu et al., Pharmaceutical Research, 1999;16(9):1412–1416; human volunteer pharmacokinetic and acute growth-hormone pharmacodynamic study.